deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT02769832

Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer

Phase II Study of Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer or Those With Progression on First Line Therapy

Sponsor: Celgene Corporation

Conditions Small Cell Lung Cancer (SCLC)
Interventions Gemcitabine Nab-paclitaxel
Updated 15 times since 2017 Last updated: Jul 16, 2025 Started: Aug 29, 2016 Primary completion: Sep 23, 2021 Completion: Jul 7, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Small Cell Lung Cancer (SCLC), this trial is completed. The trial is conducted by Celgene Corporation and has accumulated 15 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Nov 2017 · 9 months · monthly snapshot~Nov 2017 – ~Jun 2018 · 7 months · monthly snapshot~Jun 2018 – ~Feb 2019 · 8 months · monthly snapshot~Feb 2019 – ~Jun 2019 · 4 months · monthly snapshot~Jun 2019 – ~Aug 2019 · 2 months · monthly snapshot~Aug 2019 – ~Sep 2020 · 13 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Aug 2023 · 23 months · monthly snapshot~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Aug 2025 · 11 months · monthly snapshot~Aug 2025 – present · 11 months · monthly snapshot

Change History

15 versions recorded

  1. Aug 2025 — Present [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Sep 2024 — Aug 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Aug 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2024 — Aug 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Aug 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 10 earlier versions

  1. Sep 2021 — Aug 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  3. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  4. Aug 2019 — Sep 2020 [monthly]

    Recruiting PHASE2

  5. Jun 2019 — Aug 2019 [monthly]

    Recruiting PHASE2

  6. Feb 2019 — Jun 2019 [monthly]

    Recruiting PHASE2

  7. Jun 2018 — Feb 2019 [monthly]

    Recruiting PHASE2

  8. Nov 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

  9. Feb 2017 — Nov 2017 [monthly]

    Recruiting PHASE2

  10. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Aug 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Celgene Corporation
  • Muhammad Furqan
Data source: University of Iowa

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations